RPGR — retinitis pigmentosa GTPase regulator

The RPGR gene provides essential instructions for making a protein that is critical for normal vision. Inside the eye, there are specialized light-sensing cells called photoreceptors (rods and cones). These cells have a unique structure with a narrow bridge, called a connecting cilium, that links the area where proteins are made to the area where light is detected. The RPGR protein acts like a traffic controller at this bridge, ensuring that vital materials, such as light-sensitive proteins, are properly transported to where they need to be. Without this transport system, the photoreceptor cells cannot function correctly. When there is a mutation or spelling mistake in the RPGR gene, the protein is either missing or doesn't work properly. As a result, the essential materials get stuck and build up in the wrong parts of the cell. This traffic jam is toxic to the photoreceptors, causing them to gradually sicken and die. Because rod cells (responsible for night and peripheral vision) are usually affected first, patients typically experience night blindness in childhood, followed by a progressive narrowing of their visual field, often leading to severe vision loss or legal blindness in adulthood. In some cases, the mutation affects cone cells first, leading to early problems with central vision and color perception. The RPGR gene is located on the X chromosome, which means the disease it causes—X-linked retinitis pigmentosa—primarily affects males. Males have one X and one Y chromosome, so a single mutated copy of the gene is enough to cause the disease. Females have two X chromosomes, so if one has a mutation, the other normal copy can often compensate. However, because of how X chromosomes are randomly turned on or off in different cells, female carriers can have symptoms ranging from completely normal vision to severe vision loss, depending on how many of their retinal cells are using the mutated copy. Families affected by RPGR mutations should consult with a genetic counselor to understand how the condition is passed down and to explore potential eligibility for upcoming clinical trials.

Gene description: Encodes a protein involved in ciliary transport in photoreceptors, essential for their structure and function.

Patient and family guide: The RPGR gene provides essential instructions for making a protein that is critical for normal vision. Inside the eye, there are specialized light-sensing cells called photoreceptors (rods and cones). These cells have a unique structure with a narrow bridge, called a connecting cilium, that links the area where proteins are made to the area where light is detected. The RPGR protein acts like a traffic controller at this bridge, ensuring that vital materials, such as light-sensitive proteins, are properly transported to where they need to be. Without this transport system, the photoreceptor cells cannot function correctly. When there is a mutation or spelling mistake in the RPGR gene, the protein is either missing or doesn't work properly. As a result, the essential materials get stuck and build up in the wrong parts of the cell. This traffic jam is toxic to the photoreceptors, causing them to gradually sicken and die. Because rod cells (responsible for night and peripheral vision) are usually affected first, patients typically experience night blindness in childhood, followed by a progressive narrowing of their visual field, often leading to severe vision loss or legal blindness in adulthood. In some cases, the mutation affects cone cells first, leading to early problems with central vision and color perception. The RPGR gene is located on the X chromosome, which means the disease it causes—X-linked retinitis pigmentosa—primarily affects males. Males have one X and one Y chromosome, so a single mutated copy of the gene is enough to cause the disease. Females have two X chromosomes, so if one has a mutation, the other normal copy can often compensate. However, because of how X chromosomes are randomly turned on or off in different cells, female carriers can have symptoms ranging from completely normal vision to severe vision loss, depending on how many of their retinal cells are using the mutated copy. Families affected by RPGR mutations should consult with a genetic counselor to understand how the condition is passed down and to explore potential eligibility for upcoming clinical trials.

Gene function: RPGR plays a critical role in the transport of proteins to the outer segment of photoreceptor cells, which is vital for maintaining their structure and function. Mutations disrupt this transport, leading to photoreceptor degeneration and vision loss, particularly in X-linked retinitis pigmentosa.

Protein structure: The RPGR gene encodes multiple protein isoforms due to alternative splicing, with the two most prominent being the ubiquitous RPGR(1-19) and the retina-specific RPGR-ORF15. Both major isoforms share an identical N-terminal region (encoded by exons 1-14) that contains a Regulator of Chromosome Condensation 1 (RCC1)-like domain (RLD). This RLD consists of a seven-bladed beta-propeller structure formed by tandem repeats, which is structurally conserved and functions as an interaction hub for various proteins, including the small GTPase RAB8A and the ciliary protein RPGRIP1. The retina-specific RPGR-ORF15 isoform, which is critical for photoreceptor survival, diverges at its C-terminus. Instead of the isoprenylation site found in the ubiquitous isoform, the ORF15 variant features a large, highly repetitive domain rich in glutamic acid and glycine residues. This unique, low-complexity acidic domain is intrinsically disordered and is thought to act as a flexible scaffold that mediates interactions with motor proteins and the ciliary transport machinery. The full-length RPGR-ORF15 protein consists of 1,152 amino acids and localizes to the basal body and connecting cilium, where it assembles into multiprotein complexes essential for intraflagellar transport.

Molecular function: The RPGR (Retinitis Pigmentosa GTPase Regulator) gene encodes a protein that plays a fundamental role in the function and maintenance of cilia, particularly the connecting cilium of retinal photoreceptors. The N-terminal half of the RPGR protein contains a domain homologous to the regulator of chromosome condensation (RCC1), which acts as a guanine nucleotide exchange factor (GEF) for small GTPases. Through this RCC1-like domain, RPGR interacts with various small GTPases, such as RAB8A, facilitating the exchange of GDP for GTP. This interaction is crucial for the regulation of vesicular transport and ciliary biogenesis. In photoreceptors, the connecting cilium acts as a narrow transit corridor between the inner segment, where proteins are synthesized, and the outer segment, where phototransduction occurs. RPGR-ORF15, the retina-specific isoform, forms multiprotein complexes at the basal body and connecting cilium by interacting with other ciliary proteins, including RPGRIP1, SMC1, SMC3, and motor proteins like KIF3A. These complexes are essential for the directional transport of opsins and other critical outer segment proteins. Loss of functional RPGR disrupts this transport machinery, leading to the ectopic accumulation of opsins in the inner segment and cell body, which ultimately triggers photoreceptor cell death and retinal degeneration.

Expression pattern: The RPGR gene is ubiquitously expressed across various tissues, but its alternative splicing results in distinct tissue-specific isoforms. The constitutively expressed isoform, RPGR(1-19), spans 19 exons and is found in tissues such as the brain, testis, lung, and kidney. In contrast, the retina-specific isoform, RPGR-ORF15, which includes exons 1 through 14 and terminates in the specialized ORF15 exon, is predominantly expressed in the retina. Within the retina, the RPGR-ORF15 isoform is highly concentrated in the connecting cilia of both rod and cone photoreceptors. It localizes specifically to the basal bodies and the transition zone of the connecting cilium, a critical structure that bridges the inner and outer segments of photoreceptors. Beyond the retina, RPGR is also expressed in the motile cilia of the respiratory tract (bronchial and sinus epithelial cells) and in the inner ear (including the cochlea and stria vascularis), which explains the syndromic manifestations of sinorespiratory infections and hearing loss seen in some patients with specific RPGR mutations.

Mutation spectrum: The mutation spectrum of the RPGR gene is highly diverse, with over 300 pathogenic variants identified to date. The vast majority of these disease-causing mutations (approximately 60-75%) are clustered within the ORF15 exon, a highly repetitive, purine-rich region that acts as a mutational hotspot. The unusual sequence complexity of ORF15, rich in glutamic acid and glycine codons, makes it particularly susceptible to replication errors, leading to a high frequency of small deletions and insertions. The most common types of mutations found in the RPGR gene are frameshift and nonsense mutations, which typically result in a prematurely truncated, malfunctioning protein. Missense mutations, splice-site variants, and larger structural variations (such as copy number variants or multi-exon deletions) are also observed, though less frequently. Missense mutations are often located within the N-terminal RCC1-like domain (exons 1-14), disrupting the protein's ability to interact with its binding partners. The high new-mutation rate in the ORF15 region contributes to the significant proportion of sporadic cases of X-linked retinitis pigmentosa.

Pathogenic variants: 1. c.2236_2237del (p.Glu746Argfs*22): A common frameshift mutation located in the ORF15 exon, leading to a premature stop codon and a truncated protein. It is frequently associated with severe X-linked retinitis pigmentosa. 2. c.2405_2406del (p.Glu802Glyfs*32): Another prevalent frameshift deletion within the highly repetitive region of ORF15, causing classic XLRP with early-onset night blindness. 3. c.124G>T (p.Gly42*): A nonsense mutation located in the earlier exons (exon 2) affecting the RCC1-like domain, resulting in a complete loss of function of both major RPGR isoforms and causing severe retinal degeneration. 4. c.3197_3198del (p.Glu1066Glyfs*14): A frameshift mutation located toward the 3' end of the ORF15 exon. Consistent with genotype-phenotype correlations, variants in this region are often associated with X-linked cone-rod dystrophy rather than typical RP. 5. c.518G>A (p.Gly173Arg): A well-characterized missense mutation in the RCC1-like domain that disrupts the interaction between RPGR and its binding partners, such as RAB8A. This variant has been modeled in mice and is associated with a syndromic phenotype including retinal degeneration and ciliary dysfunction.

Clinical significance: Mutations in the RPGR gene are the most common cause of X-linked retinitis pigmentosa (XLRP), accounting for 70-80% of XLRP cases and about 10-15% of all retinitis pigmentosa cases. In affected males, the condition typically presents in early childhood with night blindness (nyctalopia), followed by a progressive loss of peripheral vision, eventually leading to severe visual impairment or legal blindness by the third or fourth decade of life. Clinical signs include attenuation of retinal blood vessels, bone-spicule pigmentary changes in the mid-periphery, and variable macular involvement. In addition to XLRP, RPGR mutations can cause X-linked cone-rod dystrophy (CORDX1) and atrophic macular degeneration. In cone-rod dystrophy, patients experience early loss of central vision, decreased visual acuity, photophobia, and impaired color vision, often progressing faster than typical RP. While most RPGR mutations result in non-syndromic retinal dystrophies, some patients exhibit a syndromic phenotype that includes recurrent sinorespiratory infections, primary ciliary dyskinesia, and sensorineural hearing loss, reflecting the ubiquitous role of RPGR in ciliary function across different tissues. Female carriers of RPGR mutations exhibit a wide spectrum of clinical severity due to skewed X-chromosome inactivation, ranging from asymptomatic to severe retinal degeneration comparable to affected males.

Inheritance: X-linked Recessive

Chromosomal location: Xp11.4

Genotype-phenotype correlations: There is a well-documented genotype-phenotype correlation associated with mutations in the RPGR gene, particularly concerning the location of the mutation within the highly repetitive ORF15 exon. Mutations located toward the 5' end of the ORF15 exon are predominantly associated with the classic X-linked retinitis pigmentosa (XLRP) phenotype, characterized by early rod dysfunction and progressive peripheral vision loss. Conversely, mutations situated toward the 3' end of the ORF15 exon are more frequently linked to cone-rod dystrophy (CORD) or macular degeneration phenotypes, where central vision and color perception are affected earlier and more severely. Despite these general trends, significant intrafamilial phenotypic variability exists, meaning that individuals within the same family carrying the identical RPGR mutation can exhibit different clinical presentations, ranging from typical RP to cone-rod dystrophy. This variability suggests the influence of genetic modifiers or environmental factors. In female carriers, the genotype-phenotype correlation is further complicated by the process of X-chromosome inactivation (lyonization). The severity of the retinal phenotype in heterozygous females is largely determined by the degree of skewed X-inactivation; a higher proportion of active X chromosomes carrying the mutated RPGR allele correlates with more severe disease manifestations.

Research and therapeutic approaches: Currently, there are no FDA-approved treatments specifically for RPGR-related inherited retinal diseases. Management is primarily supportive, focusing on low vision aids, mobility training, and regular monitoring of visual function. However, the landscape of therapeutic approaches is rapidly evolving, with gene therapy being the most promising strategy. Because the retina is immune-privileged and easily accessible, it is an ideal target for adeno-associated virus (AAV)-mediated gene augmentation therapy. Several gene therapy clinical trials are currently underway for RPGR-associated X-linked retinitis pigmentosa. These trials utilize AAV vectors to deliver a functional copy of the RPGR-ORF15 gene directly to the photoreceptors via subretinal injection. Notable ongoing trials include those sponsored by MeiraGTx/Janssen (e.g., botaretigene sparoparvovec, Phase 3, NCT04671433), Beacon Therapeutics (laru-zova), and Applied Genetic Technologies Corporation (AGTC). A significant technical challenge in developing these therapies has been the instability of the highly repetitive ORF15 sequence within viral vectors, which researchers have addressed by engineering codon-optimized, shortened, or stabilized versions of the gene that retain therapeutic efficacy. In addition to gene augmentation, other investigational approaches are being explored. CRISPR/Cas9 gene editing is being studied in preclinical models to correct specific RPGR mutations directly within the patient's DNA. Antisense oligonucleotides (ASOs) and read-through therapies for nonsense mutations are also under investigation. While Luxturna (voretigene neparvovec) is an approved gene therapy for IRDs, it is strictly indicated for patients with biallelic RPE65 mutations and is not applicable to patients with RPGR mutations.

Diagnostic testing: Diagnostic testing for RPGR-related inherited retinal diseases typically involves next-generation sequencing (NGS) using targeted retinal gene panels, whole exome sequencing (WES), or whole genome sequencing (WGS). A significant challenge in RPGR genetic testing is the highly repetitive, purine-rich ORF15 exon, which is a mutational hotspot but is notoriously difficult to sequence using standard short-read NGS technologies. Consequently, specialized, clinically validated assays with deep coverage or long-read sequencing techniques are often required to accurately detect variants, particularly frameshifts and small deletions/insertions within ORF15. Copy number variant (CNV) analysis is also recommended to detect larger deletions or duplications. Genetic counseling is a critical component of the diagnostic process for RPGR mutations. Because the condition follows an X-linked recessive inheritance pattern, genetic counselors must explain the risks to family members: affected males will pass the mutation to all their daughters (who become carriers) but none of their sons, while female carriers have a 50% chance of passing the mutation to each child. Given the variable expressivity in female carriers due to skewed X-inactivation, counseling should also address the potential for female carriers to develop clinical symptoms, ranging from mild visual impairment to severe retinal degeneration. Early molecular diagnosis is increasingly important as it determines eligibility for emerging gene therapy clinical trials.

Animal models: The RPGR gene has been extensively studied using various animal models, which have been crucial for understanding disease mechanisms and testing therapies. Several mouse models exist, including knockout models (e.g., Rpgr-null mice) and knock-in models (e.g., carrying the human G173R mutation or specific deletions in ORF15). In Rpgr-deficient mice, cone photoreceptors exhibit ectopic localization of cone opsins in the cell body and synapses, and rod photoreceptors show reduced levels of rhodopsin, followed by slow but progressive degeneration of both rods and cones. These findings suggest that RPGR is essential for maintaining polarized protein distribution across the connecting cilium. In addition to mice, naturally occurring dog models, such as XLPRA1 and XLPRA2, have provided valuable insights. XLPRA1 dogs, which have a five-base deletion in ORF15, show normal retinal function until about 6 months of age, followed by rod-led degeneration. XLPRA2 dogs, with a longer frameshift mutation, exhibit more severe degeneration and abnormal retinal development. Zebrafish models, such as the rpgra mutant, also demonstrate progressive retinal degeneration, mislocalization of cone outer segment proteins, and accumulation of vacuole-like structures, further confirming the conserved role of RPGR in ciliary transport across species.

Population genetics: Mutations in the RPGR gene are the most frequent cause of X-linked retinitis pigmentosa (XLRP), accounting for approximately 70-80% of all XLRP cases and up to 15% of all inherited retinal dystrophies globally. Because the disease is X-linked recessive, the prevalence of the affected phenotype is significantly higher in males, estimated at roughly 1 in 15,000 to 1 in 25,000 males, depending on the population. Carrier frequency in females is correspondingly higher, though many carriers remain asymptomatic or mildly affected. The highly repetitive nature of the ORF15 exon makes it highly susceptible to spontaneous mutations, resulting in a high rate of _de novo_ (new) mutations. Consequently, a significant proportion of patients with RPGR mutations present as sporadic cases with no prior family history of the disease. While RPGR mutations are found across all ethnicities, specific founder mutations have been occasionally reported in isolated populations, though the high overall mutation rate in ORF15 ensures a broad and diverse global mutation spectrum.

Selected references: 1. Vervoort R, et al. Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa. Nat Genet. 2000;25(4):462-466. PMID: 10932181 2. Megaw RD, et al. RPGR: Its role in photoreceptor physiology, human disease, and future therapies. Exp Eye Res. 2015;138:32-41. PMID: 26048600 3. Khanna H, et al. RPGR-ORF15, which is mutated in retinitis pigmentosa, associates with SMC1, SMC3, and microtubule transport proteins. J Biol Chem. 2005;280(40):33580-33587. PMID: 16087675 4. Hong DH, et al. A retinitis pigmentosa GTPase regulator (RPGR)-deficient mouse model for X-linked retinitis pigmentosa (RP3). Proc Natl Acad Sci U S A. 2000;97(7):3649-3654. PMID: 10725384 5. Talib M, et al. The Spectrum of Structural and Functional Abnormalities in Female Carriers of Pathogenic Variants in the RPGR Gene. Invest Ophthalmol Vis Sci. 2018;59(10):4123-4133. PMID: 30128532 6. Beltran WA, et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci U S A. 2012;109(6):2132-2137. PMID: 22308400 7. Tee JJ, et al. RPGR-associated retinopathy: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 2016;100(8):1022-1027. PMID: 26823393